Dalde, Khasimira A.
HRN: 16-62-16 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/09/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/09/2023
10/15/2023
IV
180mg
BID
Pcap C
Waiting Final Action
Indication: EmpiricEmpirical Escalation Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes